A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Asymptomatic Volunteers Who Are Infected With Either Mycobacterium Tuberculosis (M.tb.), Human Immunodeficiency Virus (HIV) or Both.
Phase of Trial: Phase I
Latest Information Update: 25 Mar 2011
At a glance
- Drugs MVA 85A (Primary)
- Indications HIV infections; Tuberculosis
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 25 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Mar 2011 Planned end date changed from 1 Apr 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.